Sorafenib: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Multikinase inhibitor, targetting Raf kinase and possibly other kinase activation by VEGF 1, 2, and 3, PDGFRβ, FLT3, c-KIT and RET * Indications include renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma, as well as certain types of acute myeloid leukemia * Can cause myelosuppression Category:Medications Category:Oncology" |
(No difference)
|
Latest revision as of 16:06, 24 November 2023
- Multikinase inhibitor, targetting Raf kinase and possibly other kinase activation by VEGF 1, 2, and 3, PDGFRβ, FLT3, c-KIT and RET
- Indications include renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma, as well as certain types of acute myeloid leukemia
- Can cause myelosuppression
